Nigeria is missing on the list of African countries that have been selected in a landmark deal to produce low-cost versions of molnupiravir, an oral COVID-19 antiviral medicine produced by Merck & Co.
Medicines Patent Pool (MPP) had negotiated a deal with Merck last year to give sublicense to
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
